Plaque Clinical Trial - Efficacy of the Disclosing Plaque Agent as a Guide

Status Completed

Clinical Trial Summary

It is more difficult to perform excellent professional oral hygiene in patients wearing orthodontic appliances. The hypothesis of the present randomized controlled trial is that the application of plaque disclosing agent allows better biofilm removal. To test this hypothesis, the patients, upon initial evaluation, will be divided in 2 study groups: - CONTROL GROUP will receive professional oral hygiene without disclosing agent - TEST GROUP will receive professional oral hygiene guided by plaque disclosing agent At the end of the professional oral hygiene session, the disclosing agent is re-applied in all patients and the percentage of residual plaque area is calculated though image software analysis (ImageJ).

Clinical Trial Description

Oral biofilm is not always visible, so its complete removal can be challenging. Applying a plaque disclosing agent before the therapy might serve as a guide to better remove biofilm. Thanks to this tool, the clinicians can clearly see where the plaque is, so its removal can be more thorough. In orthodontic patients, it is even more difficult to remove biofilm and plaque, as the fixed appliances pose an obstacle. The hypothesis is that using a plaque disclosing agent as a guide to the operator, better removal of the biofilm can be achieved. The study will be performed to assess the efficacy of disclosing plaque agent as a guide to remove biofilm and plaque in orthodontic patients during professional oral hygiene, performed with air-polishing with erythritol powder and a ultrasonic device. TRIAL DESIGN: Monocetric, pragmatic, single blinded, randomized clinical trial (RCT) of parallel design.The trial will have one-year duration. STUDY POPULATION: Orthodontic patients with plaque index above the 25% and without periodontal disease. PRIMARY OUTCOME: the percentage of area in which the disclosing plaque agent is present after the treatment (RPA: Residual Plaque Area). RPA: residual plaque area: percentage of area with residual plaque coloured by plaque disclosing agent. This will be analysed and calculated with a image analysis software (ImageJ). ;

Study Design

Related Conditions & MeSH terms

Plaque

Clinical Trial Details

NCT number	NCT05428189
Study type	Interventional
Source	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Contact
Status	Completed
Phase	N/A
Start date	October 10, 2020
Completion date	May 25, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02377310` - Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography	N/A
Completed	`NCT02980497` - Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study	N/A
Not yet recruiting	`NCT03877705` - Xylitol Chewable Tablets Versus Xylitol Chewing Gum in Geriatric Bedridden Patients	Early Phase 1
Completed	`NCT02666508` - Trial of Toothpaste to Reduce Plaque and Inflammation	N/A
Completed	`NCT04921371` - Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque	Phase 1
Completed	`NCT05138978` - Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples	Phase 2
Completed	`NCT05091216` - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients	N/A
Not yet recruiting	`NCT05031260` - COMORAL® the Oral Irrigation Unit Clinical Trial	N/A
Active, not recruiting	`NCT03022344` - DD2-Coronary Plaque Morphology and Plaque Progression	N/A
Completed	`NCT05121909` - A Study of Experimental Mouthwashes	Phase 4
Completed	`NCT06318819` - Plaque Removal Effectiveness of a Flossing Device Compared to the Conventional Flossing in Adults	N/A
Completed	`NCT03989427` - The Effectiveness of Brushing and Flossing Sequence on Control of Plaque and Gingival Inflammation	N/A
Completed	`NCT04407208` - Convalescent Plasma Therapy in Patients With COVID-19	Phase 1
Completed	`NCT05821712` - A New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems	Phase 3
Completed	`NCT05239351` - Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects	N/A
Active, not recruiting	`NCT05239117` - Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects	N/A
Completed	`NCT05120141` - A Twelve Week Study of Experimental Mouth Rinses	Phase 4
Active, not recruiting	`NCT05239130` - Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects	N/A
Completed	`NCT05239156` - Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects	N/A
Not yet recruiting	`NCT04197427` - Determination of the Safety and Efficacy of a Novel Oral Rinse on Oral Health	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy of the Disclosing Plaque Agent as a Guide to Remove the Oral Biofilm in Orthodontic Patients. — ORTOPLAK

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms